Balyasny Asset Management
AVIR icon

Balyasny Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Balyasny Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-44,346
Closed -$213K – 2638
2022
Q4 		$213K Sell
44,346
-706,727
-94% -$3.58M ﹤0.01% 2114
2022
Q3 		$4.27M Sell
751,073
-1,048,434
-58% -$8.03M 0.01% 1081
2022
Q2 		$12.8M Buy
1,799,507
+1,788,546
+16,317% +$12.2M 0.04% 569
2022
Q1 		$79K Sell
10,961
-243,657
-96% -$1.65M ﹤0.01% 2175
2021
Q4 		$2.28M Buy
+254,618
New +$3.97M 0.01% 1165
2021
Q3 		– Sell
-399,227
Closed -$8.57M – 1932
2021
Q2 		$8.57M Buy
+399,227
New +$12M 0.04% 553

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return